MINIREVIEWS
Copyright ©The Author(s) 2020.
World J Hepatol. Aug 27, 2020; 12(8): 493-505
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.493
Table 2 Characteristics and outcomes of clinical studies that evaluated the effects of liraglutide and semaglutide on non-alcoholic fatty liver disease
Ref.Type of study; countryNumber of patientsTreatmentEffects on NAFLD
Kahal et al[45], 2014Prospective; United Kingdom36Liraglutide 0.9 mg/d for 6 moSerum procollagen type 3 amino-terminal peptide levels, a marker of hepatic fibrosis, decreased in women with PCOS
Eguchi et al[46], 2014Prospective; Japan26Liraglutide 0.9 mg/d for 24-96 wkALT activity decreased. NASH decreased in 6/10 patients who underwent repeat biopsy at 96 wk
Suzuki et al[47], 2013Retrospective; Japan46Liraglutide 0.9 mg/d for 6 moLiver to kidney attenuation ratio in CT (an index of hepatic steatosis) increased
Ohki et al[48], 2012Retrospective; Japan82Liraglutide 0.9 mg/d for 340 d or sitagliptin 50-100 mg/d for 250 d or pioglitazone 15 mg/d for 1200 dALT activity was reduced with all agents. Liraglutide and pioglitazone but not sitagliptin reduced the APRI score
Jendle et al[49], 2009Randomized controlled; multicenter160Liraglutide 0.6, 1.2 or 1.8 mg/d or glimepiride 4 mg/d or placebo for 26 wkLiver to spleen attenuation ratio in CT (a marker of hepatic steatosis) increased in patients treated with liraglutide 1.8 mg/d and did not change in those treated with lower doses of liraglutide or glimepiride. ALT activity showed comparable decreases with both agents
Khoo et al[50], 2009Randomized controlled; Singapore30Liraglutide 3 mg/d for 16 wk or lifestyle modificationLiraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis, but benefits were not sustained after discontinuation, in contrast with lifestyle modification
Feng et al[51], 2017Randomized controlled; China87Liraglutide, metformin, or gliclazide for 24 wkLiraglutide has better results in improving liver function, reductions in intrahepatic fat content and HbA1c level, and weight loss than metformin and gliclazide
Bouchi et al[52], 2017Randomized controlled; Japan19Liraglutide 0.9 mg/d plus insulin or insulin alone for 14 wkLiraglutide reduces visceral fat, hepatic fat accumulation, albuminuria and micro-inflammation and improves QOL
Petit et al[53], 2017Prospective; France68Liraglutide 1.2 mg/d for 6 moLiraglutide significantly reduced liver fat content
Armstrong et al[54], 2016Double-blind, randomized, controlled; multicenter United Kingdom52Liraglutide 1.8 mg/d or placebo for 48 wkLiraglutide led to histological resolution of NASH
Smits et al[55], 2016Randomized placebo-controlled; Holland52Liraglutide 1.8 mg/d, sitagliptin 100 mg/d or placeboLiraglutide or sitagliptin treatment does not reduce hepatic steatosis or fibrosis
Zhang et al[56], 2016Randomized controlled; China835Liraglutide 1.2 mg/d or metformin 500 mg/3 times per dayLiraglutide improves the blood glucose and lipid levels as well as liver function
Tian et al[57], 2018Randomized controlled; China127Liraglutide 0.6-1.2 mg/d or metformin 1000-1500 mg/d for 12 wkLiraglutide decreases ALT levels and is more effective than metformin at alleviating liver inflammation and improving liver function
Cuthbertson et al[33], 2012Prospective; United Kingdom25Exenatide 10 mg twice daily or liraglutide 1.2 mg/dBoth liraglutide and exenatide reduce body weight, HbA1c and intrahepatic lipid accumulation
Newsome et al[58], 2019Retrospective (data from 2 trials); United Kingdom957 (trial 1) and 3297 (trial 2)Semaglutide 0.05, 0.1, 0.2, 0.3 or 0.4 mg/d for 52 wk (trial 1) and semaglutide 0.5 or 1.0 mg/wk for 104 wk (trial 2)Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes